JP2019507134A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507134A5 JP2019507134A5 JP2018540013A JP2018540013A JP2019507134A5 JP 2019507134 A5 JP2019507134 A5 JP 2019507134A5 JP 2018540013 A JP2018540013 A JP 2018540013A JP 2018540013 A JP2018540013 A JP 2018540013A JP 2019507134 A5 JP2019507134 A5 JP 2019507134A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- administered
- amount
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662287858P | 2016-01-27 | 2016-01-27 | |
| US62/287,858 | 2016-01-27 | ||
| PCT/US2017/015237 WO2017132445A1 (en) | 2016-01-27 | 2017-01-27 | Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507134A JP2019507134A (ja) | 2019-03-14 |
| JP2019507134A5 true JP2019507134A5 (https=) | 2020-03-12 |
| JP6964593B2 JP6964593B2 (ja) | 2021-11-10 |
Family
ID=59398691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540013A Expired - Fee Related JP6964593B2 (ja) | 2016-01-27 | 2017-01-27 | ホスファターゼ阻害剤を使用して骨髄異形成症候群を処置するための臨床レジメン |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20190111053A1 (https=) |
| EP (1) | EP3407887B1 (https=) |
| JP (1) | JP6964593B2 (https=) |
| CN (1) | CN109475543A (https=) |
| CA (1) | CA3051828A1 (https=) |
| WO (1) | WO2017132445A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2983661B1 (en) | 2013-04-09 | 2024-05-29 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
| DK3294287T3 (da) | 2015-05-15 | 2020-06-08 | Lixte Biotechnology Inc | Oxabicycloheptan-prodrugs |
| US20190240290A1 (en) * | 2016-08-04 | 2019-08-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Companion diagnostic for combination lenalidomide and erythropoietin treatment |
| MX2019006694A (es) | 2016-12-08 | 2019-08-21 | Lixte Biotechnology Inc | Oxabicicloheptanos para la modulacion de la respuesta inmunitaria. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008030617A2 (en) | 2006-09-07 | 2008-03-13 | Stemline Therapeutics, Inc. | Cancer therapy with cantharidin and cantharidin analogs |
| CA2676422C (en) | 2007-02-06 | 2018-10-16 | Lixte Biotechnology Holdings, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
| EP2983661B1 (en) * | 2013-04-09 | 2024-05-29 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
| US10071094B2 (en) | 2014-07-24 | 2018-09-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes |
| WO2016040877A1 (en) * | 2014-09-12 | 2016-03-17 | Lixte Biotechnology, Inc. | Human dosing of phosphatase inhibitor |
-
2017
- 2017-01-27 EP EP17744934.5A patent/EP3407887B1/en not_active Not-in-force
- 2017-01-27 JP JP2018540013A patent/JP6964593B2/ja not_active Expired - Fee Related
- 2017-01-27 WO PCT/US2017/015237 patent/WO2017132445A1/en not_active Ceased
- 2017-01-27 CA CA3051828A patent/CA3051828A1/en active Pending
- 2017-01-27 US US16/072,963 patent/US20190111053A1/en not_active Abandoned
- 2017-01-27 CN CN201780019895.5A patent/CN109475543A/zh active Pending
-
2022
- 2022-03-04 US US17/687,231 patent/US20220323433A2/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Blichfeldt et al. | Metronidazole in Crohn's disease: a double blind cross-over clinical trial | |
| JP2019507134A5 (https=) | ||
| RU2005140285A (ru) | Производные карбостирила и стабилизаторы настроения для лечения расстройств настроения | |
| CN101600438A (zh) | 疼痛疾病治疗剂 | |
| JP2018521964A5 (https=) | ||
| JP2011225596A5 (https=) | ||
| EP3383385B2 (en) | Melflufen dosage regimens for cancer | |
| Wang et al. | PEG-G-CSF and L-citrulline combination therapy for mitigating skin wound combined radiation injury in a mouse model | |
| JP2015502389A5 (https=) | ||
| WO2014038630A1 (ja) | セシウム排泄剤、有害金属排泄剤、飲食品、飼料および医薬品 | |
| Hajigholami et al. | Comparing the efficacy of Dexeroyx (Osveral) and Deferoxamine (Desferal) in reducing serum ferritin level in patients with thalassemia major | |
| Arzoo et al. | Efficacy of Intravenous Ferric Carboxymaltose Versus Iron Sucrose in the Treatment of Iron Deficiency Anemia of Pregnancy: Intravenous Ferric Carboxymaltose Versus Iron Sucrose for Iron Deficiency Anemia | |
| Porter et al. | Iron chelation | |
| Oh et al. | Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis | |
| Venon et al. | Front line treatment of elderly multiple myeloma in the era of novel agents | |
| Noguerado-Mellado et al. | Anaphylactic shock due to brentuximab-vendotin confirmed by skin test and in vitro tests | |
| Benz | Treatment of beta thalassemia | |
| Azzarà et al. | Morphological features following G-CSF treatment | |
| Zheng et al. | D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation | |
| Saba et al. | Supportive Care in Myelodysplastic Syndrome | |
| JP2012025734A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| González et al. | Intravenous iron | |
| Jerjis et al. | Impact of chemotherapy on the mobilisation, harvest and economic costs of autologous peripheral stem cell transplantation in patients with multiple myeloma | |
| Wyncoll et al. | Antibiotics by Continuous Infusion: Time for Re-evaluation? | |
| Sheridan et al. | Systemic treatment of metastatic malignant melanoma |